Role of human cytochrome P450 3A4 in the metabolism of DA-8159, a new erectogenic

Xenobiotica

Volumn 34, Issue 11-12, 2004, Pages 973-982

  Ji, H Y ^a   Lee, H W ^a   Kim, H H ^a   Kim, D S ^b   Yoo, M ^b   Kim, W B ^b   Lee, H S ^a  

^a Wonkwang University   (South Korea)

^b Dong A Pharmaceutical Company   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2 PROPOXY 5 AMINOSULFONYLPHENYL) 1 METHYL 3 PROPYL 1,6 DIHYDRO 7H PYRAZOLO[4,3 D]PYRIMIDIN 7 ONE; CHLORZOXAZONE; COMPLEMENTARY DNA; COUMARIN 7 HYDROXYLASE; CYTOCHROME P450 3A4; DA 8164; DICLOFENAC; MEPHENYTOIN; MIDAZOLAM; PACLITAXEL; PHENACETIN O DEETHYLASE; TESTOSTERONE; UDENAFIL; UNCLASSIFIED DRUG;

BIOTRANSFORMATION; CONFERENCE PAPER; CORRELATION ANALYSIS; DEALKYLATION; DRUG EFFECT; DRUG METABOLISM; DRUG TOLERABILITY; ENZYME INHIBITION; ENZYME SPECIFICITY; ERECTILE DYSFUNCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER MICROSOME; LIVER PERFUSION;

CELLS, CULTURED; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; IMPOTENCE; KINETICS; MALE; MICROSOMES, LIVER; PROTEIN INTERACTION MAPPING; PYRIMIDINES;

EID: 11244316467     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250400010898     Document Type: Conference Paper

References (33)

1. AMAKYE, D., WARD, J., BRYSON, S. and HAN, K., 2004, DA-8159-phase I studies to investigate the safety and pharmacokinetics in healthy male Caucasian subjects. Clinical Pharmacology & Therapeutics, 75, 86.
2. ARLOTTO, M. P., TRANT, J. M. and ESTABROOK, R. W. , 1991, Measurement of steroid hydroxylation reactions by high-performance liquid chromatography as indicator of P450 identity and function. Methods in Enzymology, 206, 454-462.
3. BALDWIN, S. J., BLOOMER, J. C., SMITH, G. J., AYRTON, A. D., CLARKE, S. E. and CHENERY, R. J., 1995, Ketoeonazole and sulphaphenazole as the respective selective inhibitors of P450 3A and 2C9. Xenobiotica, 25, 261-270.
4. BOEK-DOHALSKA, L., HODEK, P., SULC, M. and SUBOROVA, M., 2001, α-naphthoflavone acts as activator, and reversible or irreversible inhibitor of rabbit microsomal CYP3A6. Chemico-Biological Interactions, 138, 85-106.
5. BOURRIE, M., MEUNIER, V., BERGER, Y. and FABRE, G., 1996, Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 277, 321-332.
6. CHOI, S. J., JI, H. Y., LEE, H. Y., KIM, D. S., KIM, W. B. and LEE, H. S., 2002, In vitro metabolism of a novel phosphodiesterase-5 inhibitor DA-8159 in rat liver preparations using liquid chromatography/electrospray mass spectrometry. Biomedical Chromatography, 16, 395-399.
7. CRESPI, C. L., CHANG, T. K. and WAXMAN, D. J., 1998, High-performance liquid chromatographic analysis of CYP2C8-catalyzed paclitaxel 6α-hydroxylation. Methods in Molecular Biology, 107, 123-127.
8. DIERKS, E. A., STAMS, K. R., LIM, H. K., CORNELIUS, G., ZHANG, H. and BALL, S. E., 2001, A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metabolism & Disposition, 29, 23-29.
9. EAGLING, V. A., TJIA, J. F. and BACK, D. J., 1998, Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. British Journal of Clinical Pharmacology, 45, 107-114.
10. GUENGERICH, F. P., KIM, D. H. and IWASAKI, M., 1991, Role of human cytochrome P450 IIE1 in the oxidation of several low molecular weight cancer suspects. Chemical Research in Toxicology, 4, 168-179.
11. GUENGERICH, F. P., 1999, Cytochrome P-450 3A4: regulation and role in drug metabolism. Annual Review of Pharmacology and Toxicology, 39, 1-117.
12. GIBSON, G. G., PLANT, N. J., SWALES, K. E., AYRTON, A. and EL-SANKARY, W., 2002, Receptor-dependent transcriptional activation of CYP3A genes: induction mechanisms, species differences and interindividual variation in man. Xenobiotica, 32, 165-206.
13. HYLAND, R., ROE, E. G. H., JONES, B. C. and SMITH, D. A., 2001, Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. British Journal of Clinical Pharmacology, 51, 239-248.
14. KIM, J., KIM, S. J., JI, H. Y., JIN, J. K., LEE, S. S., KIM, D. S., YOO, M., KIM, W. B. and LEE, H. S., 2003, Simultaneous determination of a new phosphodiesterase-5 inhibitor DA-8159 and its active metabolite in human plasma by high performance liquid chromatography with tandem mass spectrometry. Chromatographia, 57, 447-450.
15. KRONBACH, T., 1991, Bufuralol, dextrmethorphan and debrisoquine as prototype substrates for human P450IID6. Methods in Enzymology, 206, 509-517.
16. LILLIBRIDGE, J. H., LIANG, B. H., KERR, B. M., WEBBER, S., QUART, B., SHETTY, B. and LEE, C. A., 1998, Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. Drug Metabolism & Disposition, 26, 609-616.
17. LEEMANN, T., TRANSON, C. and DAYER, P., 1993, Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver. Life Sciences, 52, 29-34.
18. MERRY, C., BARRY, M. G., RYAN, M., TJIA, J. F., HENNESY, M., EAGLING, V. A., MULCAHY, F. and BACK, D. J., 1999, Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. AIDS, 13, F101-F107.
19. MUIRHEAD, G. J., WULFF, M. B., FIELDING, A., KLEINERMANS, D. and BUSS, N., 2000, Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. British Journal of Clinical Pharmacology, 50, 99-107.
20. MUIRHEAD, G. J., FAULKNER, S., HARNESS, J. A. and TAUBEL, J., 2002, The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil citrate in healthy volunteers. British Journal of Clinical Pharmacology, 53, 37S-43S.
21. OH, T. Y., KANG, K. K., AHN, B. O., YOO, M. and KIM, W. B., 2000, Erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159. Archives of Pharmacol Research, 23, 471-476.
22. PERLOFF, M. D., VON MOLTKE, L. L., COURT, M. H., KOTEGAWA, T., SHADER, R. I. and GREENBLATT, D. J., 2000, Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms. Journal of Pharmacology and Experimental Therapeutics, 292, 618-628.
23. PLANT, N. J. and GIBSON, G.G., 2003, Evaluation of the toxicological relevance of CYP3A4 induction. Current Opinion in Drug Discovery and Development, 6, 50-56.
24. SHIMADA, T., YAMAZAKI, H., MIMURA, M., INUI, Y. and GUENGERICH, F. P., 1994, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414-423.
25. TASSANEEYAKUL, W., BIRKETT, D. J., VERONESE, M. E., MCMANUS, M. E., TUKEY, R. H., QUATTROCHI, L. C., GELBOIN, H. V. and MINER, J. O., 1993, Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. Journal of Pharmacology and Experimental Therapeutics, 265, 401-407.
26. VON MOLTKE, L. L., GREENBLATT, D. J., SCHMIDER, J., DUAN, S. X., WRIGHT, C. E., HARMATZ, J. S. and SHADER, R. I., 1996, Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxeteine, norfluoxeteine, and by azole antifungal agents. Journal of Clinical Pharmacology, 36, 783-791.
27. VON MOLTKE, L. L., GREENBLATT, D. J., GRASSI, J. M., GRANDA, B. W., DUAN, S. X., FOGELMAN, S. M., DAILY, J. P., HARMATZ, J. S. and SHADER, R. I., 1998, Protease inhibitors as inhibitors of human cytochromes P450: High risk associated with ritonavir. Journal of Clinical Pharmacology, 38, 106-111.
28. WARRINGTON, J. S., SHADER, R. I., VON MOLTKE, L. L. and GREENBLATT, D. J., 2000, In vitro biotransformation of sildenafil (viagra): identification of human cytochromes and potential drug interactions. Drug Metabolism & Disposition, 28, 392-397.
29. WATKINS, P. B., WRIGHTON, S. A., MAUEL, P., SCHUETS, E. G., MENDEZPICON, G., PARKER, G. A. and GUZELIAN, P. S., 1985, Identification of an inducible form of cytochrome P-450 in human liver. Proceedings of the National Academy of Sciences of the United States of America, 82, 6310-6314.
30. WANG, J. S., WEN, X., BACKMAN, J. T., TAAVITSAINEN, P., NEUBONNEN, P. J. and KIVISTO, K. T., 1999, Midazolam α-hydroxylation by human liver microsomes in vitro: inhibition by calcium channel blockers, itraconazole and ketoconazole. Pharmacology & Toxicology, 85, 157-161.
31. WRIGHTON, S. A., STEVENS, J. C., BECKER, G. W. and VANDENBRANDEN, M., 1993, Isolation and characterization of human liver cytochrome P450 2C19: Correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Archives of Biochemistry and Biophysics, 306, 240-245.
32. WRIGHTON, S. A., THUMMEL, K. E., 2000. CYP3A. In R. H. Levy, K. E. Thummel, W. F. Trager, P. D. Hansten and M. Eichelbaum (eds), Metabolic Drug Interactions (Philadelphia: Lippincott Williams & Wilkins), pp. 115-133.
33. YAMANO, S., TATSUNO, J. and GONZALEZ, F. J., 1990, The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry, 29, 1322-1329.